GlassScriptPhysician profile
Jeffrey J White
NPI 1245221563
$716.93
in general payments reported to CMS, 2019-2025
13 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.69 · 2020: $28.48 · 2021: $49.01 · 2023: $64.58 · 2024: $180 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $379.04 | 2021-2025 | Clareon, Unity, Centurion |
| Amgen INC. | $75.39 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $67.25 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $52.45 | 2021-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $30.75 | 2024 | Xdemvy |
| Allergan, INC. | $16.69 | 2019 | |
| Genentech USA, INC. | $15.73 | 2025 | Vabysmo |
| Ivantis, INC | $14.95 | 2020 | |
| Glaukos Corporation | $14.47 | 2024 | Idose |
| Bausch & Lomb Americas INC. | $13.56 | 2025 | Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.69 | 2021 | |
| Alimera Sciences, INC. | $11.43 | 2023 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.